NEW YORK ─ Cancer detection firm Micronoma on Wednesday announced the closing of $3.5 million in convertible debt financing.
The San Diego-based developer of microbiome-based cancer detection technology said that the additional financing will enable it to complete a validation study on lung cancer prediction, set up CLIA operations, establish its go-to-market strategy utilizing its Oncobiota platform, and initiate work on a second cancer target.
Existing US-based investor SymBiosis and a new European-based investor Seerave Foundation contributed to the financing.